Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
The next leap in Alzheimer’s R&D is coming, but not around the corner
While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.